Drug Profile

Daptomycin intravenous - Xellia Pharmaceuticals

Alternative Names: Cubicin

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xellia Pharmaceuticals
Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
Mechanism of Action Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Bacteraemia; Skin and soft tissue infections

Most Recent Events

06 Sep 2018 Xellia Pharmaceuticals in-licenses SPS^® (Stabilising and Protecting Solutions) formulation technology platform from LEUKOCARE
20 Oct 2017 Registered for Bacteraemia in USA (IV)
20 Oct 2017 Registered for Skin and soft tissue infections in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com